Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
IPO Year: 2014
Exchange: NASDAQ
Website: pahc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | $22.00 | Neutral | JP Morgan |
| 12/7/2023 | $9.00 | Underperform | Exane BNP Paribas |
| 12/21/2022 | $18.00 | Buy | ROTH Capital |
| 7/25/2022 | $22.00 | Equal Weight → Underweight | Barclays |
| 1/10/2022 | $23.00 | Underweight → Equal-Weight | Barclays |
| 11/18/2021 | $23.00 | Equal-Weight | Morgan Stanley |
| 8/5/2021 | $25.00 | Neutral | Credit Suisse |
| 7/7/2021 | $23.00 | Equal-Weight → Underweight | Barclays |
Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Bank of America 2025 Virtual Animal Health Summit. Chief Financial Officer, Glenn David will address financial analysts and investors on Thursday, February 27, 2025, at 10:50 AM ET. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its second quarter ended December 31, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended December 31, 2024 (compared to the three months ended December 31, 2023) Net sales of $309.3 million, an increase of $59.3 million, or 24% Net income of $3.2 million, an increase of $1.9 million Diluted earnings per share of $0.08, an increase of $0.05 Adjusted EBITDA of $48.2 million, an increase of $18.7 million, or 64% Adjusted net income of $21.9 million, an increase of $8.5 million, or 63% Adjusted diluted
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 26, 2025, to stockholders of record at the close of business on March 5, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit w
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Ms. Lee brings a wealth of expertise and leadership to our Board of Directors, most recently serving as President of Cobb Vantress LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis.
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its second quarter financial results on Wednesday, February 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 6, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its first quarter ended September 30, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended September 30, 2024 (compared to the three months ended September 30, 2023) Net sales of $260.4 million, an increase of $29.1 million, or 13% Net income of $7.0 million, an increase of $15.0 million Diluted income per share of $0.17, an increase of $0.37 Adjusted EBITDA of $30.7 million, an increase of $12.0 million, or 64% Adjusted net income of $14.1 million, an increase of $8.6 million Adjusted diluted EPS of $0.35,
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 18, 2024, to stockholders of record at the close of business on November 27, 2024. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please vi
Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the successful completion of the acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc. (NYSE:ZTS). This acquisition marks a significant step in furthering Phibro's purpose to optimize global animal health and nutrition for better lives and a more sustainable world. "Adding this new lineup of medicated feed additives and water-soluble products across cattle, swine and poultry will complement and expand Phibro's species and product portfolios, helping customers meet the highest standards of animal care, prevent disease, and enhance nutrition around the world," said Jack C
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its first quarter financial results on Wednesday, November 6, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 7, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To acc
Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. Chief Financial Officer, Glenn David along with Chief Operating Officer, Larry Miller will address financial analysts and investors on Thursday, September 5, 2024, at 1:05 PM ET at the New York Marriott Marquis. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal h
SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Joyce J. Lee, MBA, as a Class II director of the Company, effective immediately. Ms. Lee will be an independent director. Her appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Ms. Lee brings a wealth of expertise and leadership to our Board of Directors, most recently serving as President of Cobb Vantress LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis.
Damian Finio to Succeed Javier Daly as Chief Financial Officer TRENTON, N.J., Sept. 6, 2023 /PRNewswire/ -- TerraCycle Inc., the international leader in innovative sustainability solutions, today announced Damian Finio will join the company's global leadership team as Chief Financial Officer, effective October 2. Finio most recently served as Chief Financial Officer of Phibro Animal Health Corporation (NASDAQ:PAHC) and joins TerraCycle with more than 30 years of financial management experience, primarily in the life sciences industry having spent nearly half of his career at
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately. Mr. Bernal will be an independent director. His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Mr. Bernal recently became Chief Executive Officer of PetDx® – The Liquid Biopsy Company for Pets™, a company based in San Diego, CA, and focused on early detection of cancer using Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its second quarter ended December 31, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended December 31, 2024 (compared to the three months ended December 31, 2023) Net sales of $309.3 million, an increase of $59.3 million, or 24% Net income of $3.2 million, an increase of $1.9 million Diluted earnings per share of $0.08, an increase of $0.05 Adjusted EBITDA of $48.2 million, an increase of $18.7 million, or 64% Adjusted net income of $21.9 million, an increase of $8.5 million, or 63% Adjusted diluted
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 26, 2025, to stockholders of record at the close of business on March 5, 2025. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit w
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its second quarter financial results on Wednesday, February 5, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 6, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its first quarter ended September 30, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended September 30, 2024 (compared to the three months ended September 30, 2023) Net sales of $260.4 million, an increase of $29.1 million, or 13% Net income of $7.0 million, an increase of $15.0 million Diluted income per share of $0.17, an increase of $0.37 Adjusted EBITDA of $30.7 million, an increase of $12.0 million, or 64% Adjusted net income of $14.1 million, an increase of $8.6 million Adjusted diluted EPS of $0.35,
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 18, 2024, to stockholders of record at the close of business on November 27, 2024. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please vi
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its first quarter financial results on Wednesday, November 6, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 7, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To acc
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2024 and provided its financial guidance for the year ending June 30, 2025. Highlights for the three months ended June 30, 2024 (compared to the three months ended June 30, 2023) Net sales of $273.2 million, an increase of $18.1 million, or 7% Net income of $0.8 million, a decrease of $10.7 million Diluted earnings per share of $0.02, a decrease of $0.26 Adjusted EBITDA of $33.4 million, an increase of $1.1 million, or 3% Adjusted net income of $16.7 million, an increase of $1.5 million, or 10% Adjusted diluted
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its fourth quarter and fiscal year 2024 financial results on Wednesday, August 28, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 29, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 25, 2024, to stockholders of record at the close of business on September 4, 2024. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its third quarter ended March 31, 2024, and its updated financial guidance for the year ending June 30, 2024. Highlights for the three months ended March 31, 2024 (compared to the three months ended March 31, 2023) Net sales of $263.2 million, an increase of $17.6 million, or 7% Net income of $8.4 million, a decrease of $1.6 million Diluted earnings per share of $0.21, a decrease of $0.04 Adjusted EBITDA of $29.7 million, an increase of $2.3 million, or 9% Adjusted net income of $12.7 million, an increase of $1.1 million, or 9% Adjusted diluted EPS of $0.31, a
SCHEDULE 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SCHEDULE 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
10-Q - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
8-K/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
10-Q - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
3 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
3 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
3 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
3 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
JP Morgan initiated coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $22.00
Exane BNP Paribas initiated coverage of Phibro Animal Health with a rating of Underperform and set a new price target of $9.00
ROTH Capital initiated coverage of Phibro Animal Health with a rating of Buy and set a new price target of $18.00
Barclays downgraded Phibro Animal Health from Equal Weight to Underweight and set a new price target of $22.00
Barclays upgraded Phibro Animal Health from Underweight to Equal-Weight and set a new price target of $23.00
Morgan Stanley initiated coverage of Phibro Animal Health with a rating of Equal-Weight and set a new price target of $23.00
Credit Suisse resumed coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $25.00
Barclays downgraded Phibro Animal Health from Equal-Weight to Underweight and set a new price target of $23.00
Morgan Stanley reiterated coverage of Phibro Animal Health with a rating of Underweight and set a new price target of $22.00 from $19.00 previously